Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Assistance Publique - Hôpitaux de Paris
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Head And Neck Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 68Ga-RGD (this asset) | Assistance Publique - Hôpitaux de Paris | P2 | CCC · 53 |
| Cyclophosphamide | National Cancer Institute (NCI) | P2 | BB |
| Pembrolizumab | National Cancer Institute (NCI) | P2 | BB |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Tadalafil | University of California, San Diego | P2 | B |
| Sapanisertib | National Cancer Institute (NCI) | P2 | CCC |
| Trametinib | National Cancer Institute (NCI) | P2 | CCC |
| Ulixertinib | National Cancer Institute (NCI) | P2 | CCC |
| Vismodegib | National Cancer Institute (NCI) | P2 | CCC |
+42 more in the Head And Neck Carcinoma cohort
Other indications for 68Ga-RGD
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 53 |
| Brain Neoplasm | — | Early P1 | C · 38 |
| Prostate Cancer | — | Early P1 | C · 33 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 68Ga-RGD in Head And Neck Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/68ga-rgd-head-and-neck-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →